down arrow

BioMarin Pharmaceutical, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09061G1013
USD
53.82
-0.07 (-0.13%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Halozyme Therapeutics, Inc.
Gilead Sciences, Inc.
BioMarin Pharmaceutical, Inc.
Amgen, Inc.
Moderna, Inc.
Biogen, Inc.
Illumina, Inc.
Elanco Animal Health, Inc.
Bio-Techne Corp.
Vaxcyte, Inc.
Immunovant, Inc.
Why is BioMarin Pharmaceutical, Inc. ?
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Operating profit has grown by an annual rate 91.42%
3
The company has declared Positive results for the last 5 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 766.77 MM
  • INTEREST COVERAGE RATIO(Q) Highest at 11,947.33
  • ROCE(HY) Highest at 11.62%
4
With ROE of 9.49%, it has a fair valuation with a 1.88 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -13.52%, its profits have risen by 147.1% ; the PEG ratio of the company is 0.1
5
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
7
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -13.52% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to BioMarin Pharmaceutical, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is BioMarin Pharmaceutical, Inc. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
BioMarin Pharmaceutical, Inc.
-14.83%
-1.03
31.23%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
10.81%
EBIT Growth (5y)
91.42%
EBIT to Interest (avg)
11.59
Debt to EBITDA (avg)
0.18
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.42
Tax Ratio
22.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
3.46%
ROE (avg)
7.17%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.88
EV to EBIT
16.28
EV to EBITDA
14.21
EV to Capital Employed
1.99
EV to Sales
3.49
PEG Ratio
0.14
Dividend Yield
NA
ROCE (Latest)
12.21%
ROE (Latest)
9.49%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

30What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 766.77 MM

INTEREST COVERAGE RATIO(Q)

Highest at 11,947.33

ROCE(HY)

Highest at 11.62%

RAW MATERIAL COST(Y)

Fallen by -2.18% (YoY

CASH AND EQV(HY)

Highest at USD 2,704.46 MM

DEBT-EQUITY RATIO (HY)

Lowest at -13.61 %

NET SALES(Q)

Highest at USD 827.47 MM

OPERATING PROFIT(Q)

Highest at USD 320.07 MM

OPERATING PROFIT MARGIN(Q)

Highest at 38.68 %

PRE-TAX PROFIT(Q)

Highest at USD 321.94 MM

NET PROFIT(Q)

Highest at USD 259.97 MM

EPS(Q)

Highest at USD 1.23

-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 0.51 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.93 times

Here's what is working for BioMarin Pharmaceutical, Inc.
Interest Coverage Ratio
Highest at 11,947.33 and Grown
In each period in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Cash Flow
Highest at USD 766.77 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit
At USD 321.94 MM has Grown at 82.28%
over average net sales of the previous four periods of USD 176.61 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 259.97 MM has Grown at 89.22%
over average net sales of the previous four periods of USD 137.39 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales
Highest at USD 827.47 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 320.07 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at 38.68 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD 321.94 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 259.97 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD 1.23
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv
Highest at USD 2,704.46 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -13.61 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -2.18% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for BioMarin Pharmaceutical, Inc.
Inventory Turnover Ratio
Lowest at 0.51 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 3.93 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."